SNDX – Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc.SNDX
$9.49Name : Syndax Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $854,368,128.00
EPSttm : -2.37
Syndax Pharmaceuticals, Inc.
$9.49
0.63%$0.06
SNDX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
22
Margin Of Safety %
Put/Call OI Ratio
0.32
EPS Next Q Diff
0.47
EPS Last/This Y
1.16
EPS This/Next Y
1.34
Price
9.46
Target Price
35.9
Analyst Recom
1.09
Performance Q
-52.07
Upside
-974.1%
Beta
0.49
Ticker: SNDX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | SNDX | 9.01 | 0.16 | 1.74 | 29512 |
| 2026-10-13 | SNDX | 13.95 | 0.16 | 1.01 | 29972 |
| 2026-10-14 | SNDX | 13.53 | 0.17 | 1.90 | 31199 |
| 2026-10-15 | SNDX | 13.65 | 0.15 | 1.46 | 30892 |
| 2026-10-16 | SNDX | 12.91 | 0.16 | 1.15 | 31204 |
| 2026-10-19 | SNDX | 13.1 | 0.19 | 0.58 | 24094 |
| 2026-10-20 | SNDX | 13.24 | 0.19 | 0.41 | 24393 |
| 2026-10-21 | SNDX | 13.15 | 0.19 | 0.00 | 24679 |
| 2026-10-22 | SNDX | 13.56 | 0.19 | 0.37 | 24693 |
| 2026-10-23 | SNDX | 13.39 | 0.19 | 1.24 | 24841 |
| 2026-10-26 | SNDX | 13.2 | 0.20 | 0.49 | 25090 |
| 2026-10-27 | SNDX | 13.68 | 0.19 | 0.19 | 25121 |
| 2026-10-28 | SNDX | 14.32 | 0.19 | 29.94 | 25264 |
| 2026-10-29 | SNDX | 14.14 | 0.24 | 37.77 | 26362 |
| 2026-10-30 | SNDX | 13.64 | 0.42 | 0.40 | 30247 |
| 2026-11-02 | SNDX | 12.9 | 0.42 | 0.89 | 30357 |
| 2026-11-03 | SNDX | 14.29 | 0.42 | 1.03 | 30611 |
| 2026-11-04 | SNDX | 10.48 | 0.43 | 0.90 | 31426 |
| 2026-11-05 | SNDX | 9.32 | 0.33 | 0.69 | 30481 |
| 2026-11-06 | SNDX | 9.52 | 0.33 | 0.07 | 30525 |
| 2026-11-09 | SNDX | 9.55 | 0.32 | 0.16 | 30940 |
| 2026-11-10 | SNDX | 9.47 | 0.32 | 0.47 | 30729 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | SNDX | 16.54 | 32.1 | - | -1.95 |
| 2026-10-13 | SNDX | 13.98 | 32.1 | - | -1.95 |
| 2026-10-14 | SNDX | 13.53 | 32.1 | - | -1.98 |
| 2026-10-15 | SNDX | 13.64 | 32.1 | - | -1.98 |
| 2026-10-16 | SNDX | 12.91 | 30.4 | - | -1.98 |
| 2026-10-19 | SNDX | 13.11 | 30.4 | - | -1.98 |
| 2026-10-20 | SNDX | 13.11 | 30.4 | - | -1.98 |
| 2026-10-21 | SNDX | 13.25 | 30.4 | - | -1.98 |
| 2026-10-22 | SNDX | 13.56 | 30.4 | - | -1.98 |
| 2026-10-23 | SNDX | 13.39 | 30.4 | - | -1.98 |
| 2026-10-26 | SNDX | 13.21 | 30.4 | - | -1.98 |
| 2026-10-27 | SNDX | 13.68 | 30.4 | - | -1.98 |
| 2026-10-28 | SNDX | 14.32 | 30.4 | - | -1.98 |
| 2026-10-29 | SNDX | 14.13 | 30.4 | - | -1.98 |
| 2026-10-30 | SNDX | 13.63 | 31.0 | - | -1.94 |
| 2026-11-02 | SNDX | 13.07 | 31.0 | - | -1.94 |
| 2026-11-04 | SNDX | 10.47 | 31.0 | - | -1.95 |
| 2026-11-05 | SNDX | 9.32 | 31.0 | - | -1.95 |
| 2026-11-06 | SNDX | 9.52 | 38.0 | - | -1.91 |
| 2026-11-09 | SNDX | 9.55 | 38.0 | - | -1.91 |
| 2026-11-10 | SNDX | 9.46 | 38.0 | - | -2.13 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | SNDX | -1.28 | 11.26 | 22.47 |
| 2026-10-13 | SNDX | -1.28 | 11.26 | 22.47 |
| 2026-10-14 | SNDX | -1.28 | 11.26 | 22.47 |
| 2026-10-15 | SNDX | -1.28 | 11.26 | 22.47 |
| 2026-10-16 | SNDX | -1.28 | 11.26 | 22.47 |
| 2026-10-19 | SNDX | -1.28 | 11.16 | 22.47 |
| 2026-10-20 | SNDX | -1.28 | 11.16 | 22.47 |
| 2026-10-21 | SNDX | -1.28 | 11.16 | 22.47 |
| 2026-10-22 | SNDX | -1.28 | 11.16 | 22.47 |
| 2026-10-23 | SNDX | -1.28 | 11.16 | 22.47 |
| 2026-10-26 | SNDX | -1.28 | 10.34 | 22.47 |
| 2026-10-27 | SNDX | -1.28 | 10.34 | 22.18 |
| 2026-10-28 | SNDX | -1.28 | 10.34 | 22.18 |
| 2026-10-29 | SNDX | -1.28 | 10.34 | 22.18 |
| 2026-10-30 | SNDX | -1.28 | 10.34 | 22.18 |
| 2026-11-02 | SNDX | -1.38 | 10.39 | 22.18 |
| 2026-11-03 | SNDX | -1.38 | 10.39 | 22.18 |
| 2026-11-05 | SNDX | -1.37 | 10.39 | 22.00 |
| 2026-11-06 | SNDX | -1.37 | 10.39 | 22.00 |
| 2026-11-09 | SNDX | -1.37 | 7.72 | 22.00 |
| 2026-11-10 | SNDX | -1.37 | 7.72 | 22.00 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.55
Avg. EPS Est. Current Quarter
-0.48
Avg. EPS Est. Next Quarter
-0.08
Insider Transactions
-1.37
Institutional Transactions
7.72
Beta
0.49
Average Sales Estimate Current Quarter
96
Average Sales Estimate Next Quarter
Fair Value
Quality Score
34
Growth Score
38
Sentiment Score
2
Actual DrawDown %
68.3
Max Drawdown 5-Year %
-69.9
Target Price
35.9
P/E
Forward P/E
PEG
P/S
2.95
P/B
P/Free Cash Flow
EPS
-2.37
Average EPS Est. Cur. Y
-2.13
EPS Next Y. (Est.)
-0.78
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
-72.32
Relative Volume
1.25
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.18
EBIT Estimation
◆
SNDX
Healthcare
$9.49
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
25.8
Range 1M
3%
Sup Dist
3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
34.7%
EPS NY
54.2%
52W%
1.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+278.3% upside
Upside
+278.3%
Quality
34
SNDX — P/E HistoricalBiotechnology
Syndax Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 298
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
SNDX
Latest News
—
Caricamento notizie per SNDX…
stock quote shares SNDX – Syndax Pharmaceuticals, Inc. Stock Price stock today
news today SNDX – Syndax Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SNDX – Syndax Pharmaceuticals, Inc. yahoo finance google finance
stock history SNDX – Syndax Pharmaceuticals, Inc. invest stock market
stock prices SNDX premarket after hours
ticker SNDX fair value insiders trading